2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Hepatocellular
37
Carcinoma, Non-Small-Cell Lung
24
Melanoma
19
Squamous Cell Carcinoma of Head and Neck
18
Colorectal Neoplasms
16
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Lung Neoplasms
10
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Carcinoma, Renal Cell
9
Neoplasms
8
Cholangiocarcinoma
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Mesothelioma, Malignant
5
Fallopian Tube Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Mesothelioma
3
Kidney Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
tremelimumab
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA